NIH R01 · 2024
PROJECT SUMMARY Preterm birth (PTB), or birth before 37 weeks of gestation, was the second leading cause of infant death in the US in 2017. Each year, more than $26 billion is spent on treatment and care of babies born prematurely, not accounting for the lifelong impact of developmental and cognitive impairments. Earlier this year, the FDA issued a recommendation that the synthetic progestin 17-hydroxyprogesterone caproate (OHPC, Makena®), the only approved product for PTB prevention, be withdrawn from the market due to lack of clinical benefit in a required post-market study. New and innovative therapeutic options for preventing PTB are desperately needed, but the etiology of PTB is…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.